A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC

Abstract Panobinostat (pano) is an FDA-approved histone deacetylase inhibitor. There is interest in evaluating alternate dosing schedules and novel combinations of pano for the treatment of upper aerodigestive and lung malignancies; thus we evaluated it in combination with Taxol, a chemotherapeutic...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Leleesha Samaraweera, Alfred Adomako, Alicia Rodriguez-Gabin, Hayley M. McDaid
Format: article
Langue:EN
Publié: Nature Portfolio 2017
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/8bf6e32804f94f5480e8b18e2a01b3ef
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!